Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

MLA

Alexander Spira, et al. “Identification of HMGA2 as a Predictive Biomarker of Response to Bintrafusp Alfa in a Phase 1 Trial in Patients with Advanced Triple-Negative Breast Cancer.” Frontiers in Oncology, vol. 12, Dec. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.981940.

APA

Alexander Spira, Ahmad Awada, Nicolas Isambert, David Lorente, Nicolas Penel, Yue Zhang, Laureen S. Ojalvo, Christine Hicking, P. Alexander Rolfe, Christian Ihling, Isabelle Dussault, George Locke, & Christian Borel. (2022). Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.981940

Chicago

Alexander Spira, Ahmad Awada, Nicolas Isambert, David Lorente, Nicolas Penel, Yue Zhang, Laureen S. Ojalvo, et al. 2022. “Identification of HMGA2 as a Predictive Biomarker of Response to Bintrafusp Alfa in a Phase 1 Trial in Patients with Advanced Triple-Negative Breast Cancer.” Frontiers in Oncology 12 (December). doi:10.3389/fonc.2022.981940.